Treatment with empagliflozin attenuated hyperfiltration in 37 people with type I diabetes not on RAS inhibition and resulted in an increase in urinary levels of angiotensinogen, ACE, ACE-2, rise in plasma angiotensin I, II and renin activity as well as a fall in plasma ACE activity (28, 29). This evidence concerns the gene REN and type 1 diabetes mellitus.